Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015718 | 1.00 | MEN1 (0.50) | MEN1KMT2ANPC1RAB9ADDB1 | |
| SCHEMBL25868406 | 0.90 | MCHR1 (0.49) | ROCK2 | |
| SCHEMBL20329795 | 0.89 | KMT2A (0.47) | MEN1KMT2ANPC1RAB9ADDB1 | |
| SCHEMBL4791124 | 0.89 | KMT2A (0.47) | MEN1KMT2ANPC1RAB9ADDB1 | |
| SCHEMBL17779651 | 0.87 | MEN1 (0.46) | MEN1KMT2ANPC1RAB9ADDB1 | |
| SCHEMBL12528001 | 0.83 | HTT (0.48) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL25269677 | 0.81 | HDAC6 (0.46) | MEN1KMT2APOLBALDH1A1USP2 | |
| SCHEMBL25868401 | 0.81 | ROCK2 (0.50) | MEN1KMT2ARAB9AALDH1A1MAPT | |
| SCHEMBL1829366 | 0.81 | HSD11B1 (0.53) | KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL19327276 | 0.79 | ROCK2 (0.48) | MEN1KMT2ANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0106988-A1 | Pharmacologically active lactam derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | claimed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-8841282-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8765736-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765736-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| WO-2009040659-A2 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (DE) | 2009-04-02 | — | — | WO | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008047883-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-24 | — | — | WO | disclosed |
| EP-1239009-A2 | Process for the preparation of asymmetric methine dyestuffs | BAYER AG (DE) | 2002-09-11 | — | — | EP | disclosed |
| EP-0756590-A1 | SYNTHESIS OF PROTOTYPES FOR RENIN INHIBITORS | Novartis AG (CH) | 1997-02-05 | — | — | EP | disclosed |
| WO-1995029150-A1 | SYNTHESIS OF PROTOTYPES FOR RENIN INHIBITORS | CIBA-GEIGY AG (CH) | 1995-11-02 | — | — | WO | disclosed |
| EP-0106988-A1 | Pharmacologically active lactam derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | MEN1 2498/4885KMT2A 2855/4885NPC1 415/4885 |
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | MEN1 2498/4885KMT2A 2855/4885NPC1 415/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | MEN1 2994/4885KMT2A 2967/4885NPC1 3482/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | MEN1 3662/4885KMT2A 1859/4885NPC1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.